Abstract: Objective To investigate the clinical efficacy and safety of Labetalol Hydrochloride combined with salvia miltiorrhiza injection in treatment of patients with gestational period hypertension. Methods Total 78 cases of gestational period hypertension in our hospital from November, 2015 to April, 2017 were randomly divided into control group (n=39) and study group (n=39) according to random number table. The control group was treated with labetalol hydrochloride and the study group was treated with labetalol hydrochloride combined with salvia miltiorrhiza injection. The course was 10 days. The clinical efficacy, DBP, SBP, serum β2-MG and Hcy levels, the maternal and infant outcomes and rate of adverse reactions were compared between two groups. Results The total effective rate of the study group was 94.87%, which was higher than that in the control group (74.36%), P<0.05. After the treatment, the DBP and SBP in the two groups were decreased, and the changed degree of DBP and SBP in study group were lower than those in control group (t=15.760, P<0.001; t=10.708, P<0.001). After the treatment, the level of β2-MG and Hcy in two group were decreased compared with before treatment, and the decreased degree of study group was lower than those in control group (t=21.121, P<0.001; t=22.803, P<0.001). The rate of adverse pregnancy outcome in study group (23.08%) was lower than that in control group (46.15%, χ²=4.588, P=0.032). The incidences of adverse reactions in study group (15.38%) was not statistically significant compared with the control group (10.26%),χ²=0.459, P=0.458. Conclusion Labetalol hydrochloride combined with Salvia miltiorrhiza injection in the treatment of gestational period hypertension can effectively reduce the blood pressure, improve the treatment effect, improve serum Hcy, β2-MG levels and maternal and child outcomes. It has high efficiency and safety, and is worthy of clinical promotion.